Last reviewed · How we verify
Autologous serum — Competitive Intelligence Brief
marketed
Autologous biological product
Ophthalmology
Small molecule
Live · refreshed every 30 min
Target snapshot
Autologous serum (Autologous serum) — Anita Syla Lokaj. Autologous serum is a patient's own blood serum used topically to provide growth factors and immunomodulatory components that promote tissue healing and reduce inflammation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Autologous serum TARGET | Autologous serum | Anita Syla Lokaj | marketed | Autologous biological product |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Autologous biological product class)
- Anita Syla Lokaj · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Autologous serum CI watch — RSS
- Autologous serum CI watch — Atom
- Autologous serum CI watch — JSON
- Autologous serum alone — RSS
- Whole Autologous biological product class — RSS
Cite this brief
Drug Landscape (2026). Autologous serum — Competitive Intelligence Brief. https://druglandscape.com/ci/autologous-serum. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab